Christopher Chiu

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas

T. Salcedo, R. Oliveri, T. Ahmadi, 2022, Clinical pharmacology and therapeutics.

Fucosyl Monosialoganglioside: Quantitative analysis of specific potential biomarkers of lung cancer in biological matrices using immunocapture extraction/tandem mass spectrometry.

T. Olah, M. Srinivasan, J. Hogan, 2018, Rapid communications in mass spectrometry : RCM.

987 Comprehensive immunophenotyping and genomics from single blood tube for T-cell dynamics in clinical trials

M. Ma-Edmonds, M. Fereshteh, Jordan M. Blum, 2022, Regular and Young Investigator Award Abstracts.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

T. Phillips, P. Lugtenburg, M. Hutchings, 2022, Blood.